Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
第一作者:
Julia K,Rotow
第一单位:
Department of Medicine, University of California, San Francisco, California.;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
作者:
主题词
老年人(Aged);动物(Animals);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);外显子(Exons);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);MAP激酶信号系统(MAP Kinase Signaling System);男(雄)性(Male);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);中年人(Middle Aged);分子靶向治疗(Molecular Targeted Therapy);突变(Mutation);癌基因蛋白质p21(ras)(Oncogene Protein p21(ras));蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-met(Proto-Oncogene Proteins c-met);治疗结果(Treatment Outcome);肿瘤细胞, 培养的(Tumor Cells, Cultured)
DOI
10.1158/1078-0432.CCR-19-1667
PMID
31548343
发布时间
2022-01-29
- 浏览0

Clinical cancer research
439-449页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文